Codiak BioSciences, Inc. appointed Richard Brudnick as Chief Business Officer and Head of Strategy. Mr. Brudnick will serve on the executive leadership team and report to Codiak's president and CEO, Douglas E. Williams, Ph.D. Prior to joining Codiak, Mr. Brudnick was Executive Vice President of Business Development and Alliance Management at Bioverativ, Inc. Prior to Bioverativ's acquisition by Sanofi in March 2018, Mr. Brudnick led business development efforts to build a significant pipeline in rare blood disorders including an acquisition.